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Macrophage infiltration is a hallmark in the majority of solid tumors. Our studies demonstrated that macrophages
that infiltrate human renal cells carcinoma (RCC) display markedly enhanced expression and activity of 15-lipoxygenase-2
(15-LOX2). Obtained data suggest that enhanced lipoxygenase activity in tumor-associated macrophages stimulates
cancer inflammation and causes immune dysfunction.
Advanced, metastatic RCC disease is
uniformly resistant to radiation and
chemotherapy and it represents one of
the most receptive cancers to immunother-
apy.
1 However, the clinical response is
weakened, mostly due to tumor-induced
immune suppression that represents a
major obstacle for successful cancer immu-
notherapy. Multiple immunosuppressive
mechanisms have been identified in RCC
that propagate conditions interfering with
the development and activation of an
effective anti-tumor response.
2,3 Tumor
microenvironment, which encompasses
immune, stromal and vascular cells, exerts
profound immunosuppressive and tolero-
genic activity on antigen presenting as well
as T effector cells by secretion of bioactive
proteins and lipids. Together, these factors
favor conditions that allow tumors to
escape immune recognition and foster
proliferative and metastatic potential of
tumor cells.
Growing body of evidence suggests
that cancer progression is facilitated by
enhanced production of eicosanoids that
promote cancer inflammation, immune
suppression, angiogenesis and proliferation
of malignant cells.
4,5 Eicosanoids are
enzymatic products of arachidonic acid
(AA) and can be formed by cyclooxygenase
(COX), lipoxygenase (LOX) or cyto-
chrome P-450 epoxygenase. Importantly,
eicosanoids strongly contribute to the
immunoregulatory mechanisms and may
control inflammation through regulation
of cytokine and chemokine production.
Arachidonate products of cycloxygenase
and lipoxygenase pathways can be secreted
in substantial amounts by both epithelial
cancer cells and tumor-infiltrating inflam-
matory cells including tumor-associated
macrophages and myeloid-derived sup-
pressor cells.
6,7 Numerous studies provided
clinical and pharmacological evidence for
involvement of COX2-PGE2 pathway in
the pathogenesis of various cancers, includ-
ing colon, lung, breast and bladder cancers.
The other AA metabolizing enzymes (e.g.,
lipoxygenases) have drawn less attention for
their potential roles in human tumor
initiation and/or progression.
Lipoxygenases (LOXs) are iron-contain-
ing dioxygenases that catalyze formation
of fatty acid hydroperoxides from poly-
unsaturated fatty acids.
8 The specific
bioactivities of LOXs include hydropero-
xidase, leukotriene synthase, lipoxin
synthase and hepoxylin synthase activities.
Four major types of mammalian LOXs
were described: 5-LOX, 8-LOX, 12-LOX
and 15-LOX. In humans, two distinct
subtypes of 15-LOX exist: 15-LOX1
(encoded by 15ALOX gene) and 15-
LOX2 (encoded by 15ALOXB gene).
Arachidonic acid (AA) is the major sub-
strate for 15-LOX2, whereas 15-LOX1
prefers linoleic acid as substrate but could
also metabolize AA. 15(S)-HETE is the
major metabolite of AA formed by 15-
LOX2 and 15-LOX1.
Recently we have demonstrated that
progression of human renal cell carcinoma
is associated with enhanced expression
and activity of 15-LOX2.
9 RCC
tissues are frequently infiltrated with
CD45+CD11b+CD68+HLA-DR+ tumor-
associated macrophages (TAMs). TAMs
seem to be central players in deregulated
eicosanoid production observed in RCC
because they secrete the highest levels of
major 15-LOX2 arachidonate metabolite
15(S)-HETE and highly expressed 15-
LOX2 at both gene and protein levels.
Isolated TAMs produce substantial
amounts of pro-inflammatory chemokine
CCL2 and immunosuppressive cytokine
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logous T lymphocytes resulted in dramatic
(4–10 fold) increase of IL-10 production.
Remarkably, inhibition of lipoxygenase
activity significantly reduced secretion of
CCL2 and IL-10 by TAMs, and also
prevented TAM-mediated induction of
IL-10 in T cells. In addition, TAMs were
able to induce tolerogenic transcription
factor FOXP3 and inhibitory receptor
CTLA-4 in T lymphocytes. However, the
ability of TAMs to convert T cells into
FOXP3+ T regulatory cells or induce
CTLA-4 did not depend on 15-LOX2
activity. It would be important in further
studies to delineate the mechanism by
which TAMs induce FOXP3
+ T regs in
kidney cancer.
Cancer therapy and immunomodula-
tory therapy of RCC is less effective in
treating large tumors partly due to
immune suppression associated with
advanced metastatic cancer disease.
Our data suggest that tumor-associated
macrophages play an important role in
the development of immune suppression
and T cell tolerance in human RCC
through secretion of immunosuppressive
factors and induction of immune unres-
ponsiveness in T cells. We demonstrated
that immune suppression in RCC is
closely relates to deregulated eicosanoid
metabolism in the tumor microenviron-
ment. Figure1 provides a schematic
overview of the contribution 15-LOX2-
expressing tumor-associated macrophages
in immune dysfunction in patients
with kidney cancer. This figure illustrates
that macrophages infiltrating human
RCC have a significant impact on cancer
inflammation via CCL2-mediated recruit-
ment of monocytes to the tumor site
10 and
inhibition of generation of anti-tumor
immune response via secretion of IL-10
and also by conversion of T cells into
T regs.
Our results suggest that manipulation
of deregulated metabolism of arachidonic
acid and reduction of eicosanoid levels
in tumor microenvironment represents
an attractive approach to regulate both
cancer-related inflammation and immune
suppression in human cancers including
RCC. Inhibition of 15-LOX2 activity
could potentially synergize with existing
RCC immunotherapy such as IL-2,
IFNa or dendritic-based therapy thereby
enhancing its therapeutic effect and
improving overall survival of cancer
patients.
Figure1. Tumor-associated macrophages contribute to the cancer immune suppression and cancer inflammation in RCC via enhanced 15-LOX2/15-S-
HETE pathway. Enhanced 15-LOX2 activity and elevated levels of eicosanoids of RCC tumor-microenvironment enable increased production of pro-
inflammatory chemokine CCL2. Elevated levels of CCL2 in tumor lead to migration of CCR2-expressing monocytes from peripheral blood to the tumor.
In tumor tissue recruited monocytes differentiate in 15-LOX-expressing tumor-associated macrophages (TAMs). High 15-LOX2 expression/activity in
TAMs results in elevated secretion of arachidonate metabolites and increased production of IL-10 and CCL2 by TAMs and T cells. In addition, TAMs
efficiently convert T cells into FOXP3
+ T regs. Together, elevated levels of IL-10 and T regs promote local immunosuppression and T cell tolerance in RCC
tumor microenvironment.
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